NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)